MedTrace Logo

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

NCT04720976 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2025-04-11

No results posted yet for this study

Summary

To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.

Conditions

Interventions

DRUG

JAB-3312

JAB-3312 will be administered orally, variable dose.

DRUG

Binimetinib

Binimetinib will be administered orally.

DRUG

Pembrolizumab

Pembrolizumab will be administered as an intravenous infusion.

DRUG

Sotorasib

Sotorasib will be administered orally.

DRUG

Osimertinib

Osimertinib will be administered orally.

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Allist Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-23
Primary Completion
2023-12-19
Completion
2023-12-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04720976 on ClinicalTrials.gov